CA3208892A
CA3208892A1
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agent
|
AU2022227439A
AU2022227439A1
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents
|
JP2023552249A
JP2024512283A
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents
|
PCT/AU2022/050154
WO2022178592A1
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents
|
BR112023017157A
BR112023017157A2
(en)
|
2021-02-26 |
2022-02-25 |
Solid-phase synthesis of prostate-specific membrane antigen (psma)-targeting conjugates derived from glutamate-urea-lysine (gul-derivatives) and their use as precursors of therapeutic and/or diagnostic agents
|
US18/547,286
US20240082435A1
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents
|
CN202280031347.5A
CN117355343A
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of conjugates of glutamate-urea-lysine derived (GUL derived) targeted Prostate Specific Membrane Antigen (PSMA) and their use as precursors for therapeutic and/or diagnostic agents
|
KR1020237033414A
KR20230155494A
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents.
|
MX2023010017A
MX2023010017A
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents.
|
EP22758645.0A
EP4297804A1
(en)
|
2021-02-26 |
2022-02-25 |
Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents
|